Adicet Bio, Inc. (NASDAQ: ACET) completed a one‑for‑16 reverse stock split of its common stock, effective 12:01 a.m. Eastern Time on December 30, 2025. The split reduces the number of shares outstanding from roughly 153.3 million to about 9.6 million while the company’s authorized share count remains at 300 million.
The reverse split is a strategic move to bring the company’s bid price back above Nasdaq’s minimum $1.00 requirement and to improve liquidity for investors. By consolidating shares, the company aims to stabilize trading activity and maintain its presence on the Nasdaq Capital Market.
Adicet Bio’s financial profile underscores the need for this action. The company reported a net loss of $26.9 million for the third quarter of 2025, with no revenue generated to date. Cash, cash equivalents, and short‑term investments stood at $202.1 million as of September 30, 2024, providing a runway that extends into the second half of 2026. The company’s pipeline focuses on allogeneic gamma‑delta T cell therapies for autoimmune diseases and cancer, with Phase 1 data for its lead candidate ADI‑001 showing encouraging early results.
Investor sentiment has been cautious following the announcement. Market participants expressed concern about the company’s low share price and the implications of a reverse split, which is often viewed as a signal of underlying challenges. Management emphasized that the split is a necessary compliance measure rather than an indicator of operational weakness, and it is expected to support continued access to capital markets.
The reverse split will reduce the number of shares to 9.6 million, but the company’s capital structure remains unchanged. The move is intended to preserve Nasdaq listing status, maintain liquidity, and provide a clearer platform for future capital‑raising activities as the company advances its clinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.